Levofloxacin

證據等級: L5

預測適應症: 10 個

Levofloxacin: From Bacterial Infections to Monoclonal Gammopathy (Infection Prophylaxis in Multiple Myeloma)

One-Sentence Summary

Levofloxacin is a broad-spectrum fluoroquinolone antibiotic; it is currently not marketed in South Africa (0 SAHPRA registrations) and no original-indication text is documented in this evidence pack. TxGNN scored ten new indications for this drug, but a review of the underlying evidence shows only one — monoclonal gammopathy (specifically, antibiotic prophylaxis during multiple myeloma induction therapy) — is supported by real clinical data, including a completed Phase 3 RCT (TEAMM) and multiple cohort studies. The other nine candidates (including the highest-scored one, punctate epithelial keratoconjunctivitis) have weak or no supporting evidence and are flagged Hold.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no SAHPRA license text available); Levofloxacin is generically a fluoroquinolone antibiotic used for bacterial infections
Predicted New Indication	Monoclonal gammopathy (infection prophylaxis during myeloma induction chemotherapy)
TxGNN Prediction Score	99.81% (rank 1391 of predicted indications)
Evidence Level	L1
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Note on indication selection: TxGNN’s single highest-scoring prediction was punctate epithelial keratoconjunctivitis (99.92%), but the evidence review found this mechanistically weak (the disease is typically viral/microsporidial, not bacterial, so it falls outside levofloxacin’s mechanism) and it carries only one tangentially relevant case-series citation — hence a Hold recommendation. Among all ten candidates reviewed, monoclonal gammopathy is the only one with a completed Phase 3 RCT, so it is presented here as the featured candidate. Septicemic plague (L2, “Proceed with Guardrails”) is a second notable candidate — see note below.

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for levofloxacin was not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, levofloxacin is a fluoroquinolone that kills bacteria by inhibiting DNA gyrase and topoisomerase IV, giving it broad Gram-negative and Gram-positive coverage.

The link to monoclonal gammopathy is not a direct treatment effect on plasma-cell biology or immunoglobulin production. Instead, patients newly diagnosed with multiple myeloma (a monoclonal gammopathy) have profound humoral immunodeficiency and are at high risk of serious infection during induction chemotherapy and neutropenia. Levofloxacin’s established antibacterial activity makes it useful as infection-prophylaxis, reducing bloodstream infections and febrile episodes in this vulnerable population — an indication that is adjacent to, rather than a cure for, the underlying disease.

This is supported by the UK TEAMM trial (a multicentre, double-blind, placebo-controlled Phase 3 RCT in newly diagnosed myeloma patients), which found levofloxacin prophylaxis reduced febrile episodes and possible/definite infections without significantly increasing Clostridioides difficile infection or resistant-organism carriage. Several smaller cohort studies in autologous stem-cell transplant and bortezomib-treated myeloma populations report consistent findings.

Clinical Trial Evidence

Currently no related clinical trials registered (the supporting TEAMM trial appears in the literature evidence below rather than the clinical-trials evidence field of this pack).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31668592	2019	RCT	The Lancet. Oncology	TEAMM trial: prophylactic levofloxacin in newly diagnosed myeloma reduced febrile episodes and infections vs placebo in a multicentre, double-blind, placebo-controlled Phase 3 RCT
29080369	2018	RCT	Clinical Transplantation	Retrospective comparison of ciprofloxacin vs levofloxacin prophylaxis in 297 autologous HSCT patients treated for multiple myeloma
26150022	2015	Cohort	Biol Blood Marrow Transplant	Levofloxacin prophylaxis reduced bloodstream infection and fever/neutropenia rates in myeloma patients undergoing autologous HSCT
37573150	2023	Cohort	Transplant Infectious Disease	Characterizes infectious complications after autologous HCT in myeloma patients with/without levofloxacin prophylaxis
25212681	2014	Cohort	International Journal of Hematology	Prophylactic oral levofloxacin reduced severe infection in 80 myeloma patients on bortezomib-based regimens
15791505	2005	Cohort	Clinical Infectious Diseases	Fluoroquinolone prophylaxis associated with reduced infection-related mortality in neutropenic hematologic malignancy patients
32304873	2020	Retrospective review	Biol Blood Marrow Transplant	Retrospective review of fluoroquinolone prophylaxis in autologous SCT — supports reconsidering routine use
32172361	2020	Review	Curr Hematol Malig Rep	Supportive care review in multiple myeloma, covering infection-prevention strategies including antibiotic prophylaxis
31690402	2019	HTA Report	Health Technology Assessment	Full TEAMM RCT health-technology-assessment report on prophylactic levofloxacin in newly diagnosed symptomatic myeloma
25591868	2016	Case Report	J Oncol Pharm Pract	Case of acute kidney injury from crystal nephropathy associated with combined pomalidomide and levofloxacin use — relevant safety signal for this population

Note: This is an antibiotic-prophylaxis indication, not a cytotoxic anticancer indication for levofloxacin itself — the myeloma is treated by other agents; levofloxacin’s role is infection prevention.

South Africa Market Information

Levofloxacin has no active SAHPRA registrations in this evidence pack (0 licenses, market status “Not Marketed”). No product name, dosage form, or approved indication text is available to report.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Additional context from the literature review above: one case report describes acute kidney injury (crystal nephropathy) when levofloxacin was co-administered with pomalidomide in a myeloma patient — this combination should be flagged for renal monitoring if prophylactic levofloxacin is considered alongside immunomodulatory myeloma therapy.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 3 RCT (TEAMM) plus multiple supportive cohort studies establish that levofloxacin prophylaxis reduces febrile/infectious complications in newly diagnosed myeloma patients during induction therapy or transplant-related neutropenia. This is an infection-prevention use, not a direct treatment for the malignancy, so the indication scope must be defined narrowly (prophylaxis during defined periods of immunosuppression/neutropenia) rather than as general treatment of monoclonal gammopathy.

To proceed, the following is needed:

TFDA/SAHPRA-equivalent Professional Information (PI) warnings and contraindications — currently a Blocking data gap (DG001), required before any safety assessment
Detailed mechanism-of-action documentation (DG002)
A SAHPRA regulatory pathway assessment, since levofloxacin has no current South African registration (market entry or import mechanism would be a prerequisite for any prophylactic-use protocol)
Local antimicrobial-stewardship review, given fluoroquinolone resistance and C. difficile risk considerations raised in the TEAMM trial literature
Renal-safety monitoring protocol for co-administration with immunomodulatory myeloma agents (per the pomalidomide case report above)

Other candidate of note (not detailed above): Septicemic plague (evidence level L2, “Proceed with Guardrails”) is supported by non-human-primate efficacy data underlying a 2012 US FDA Animal Rule approval; any use in South Africa would need an independent regulatory pathway assessment. The remaining eight predicted indications in this batch (punctate epithelial keratoconjunctivitis, hyperamylasemia, polyclonal hyperviscosity syndrome, congenital analbuminemia, blood group incompatibility, premalignant hematological disease, hematological disease with acquired peripheral neuropathy, congenital hematological disorder) have evidence level L4–L5 with no or only incidental supporting literature and are recommended Hold.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.